Biogen (BIIB) announced that the US FDA has granted Breakthrough Therapy Designation for litifilimab for the treatment of cutaneous lupus erythematosus.
Importance
Level 1
#BIOGEN IDEC INC#BIIB.US#FDA#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#BIOGEN INC#BIIB#US EQUITIES